ALS Biopharma Press Release


Doylestown, PA. May 25, 2017:

ALS Biopharma, LLC is pleased to announce that the U.S. Food and Drug Administration (FDA) has provided fast-track designation to trigriluzole for the treatment of ataxia (see here). Trigriluzole, also known as FC-4157 and BHV-4157, is an investigational new drug being developed by Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”). Trigriluzole was first prepared at Fox Chase Chemical Diversity Center, Inc. funded by SBIR grants from the National Institutes of Health (R44CA156781), in collaboration with ALS Biopharma.




Back to Press Releases